HUTCHMED (NASDAQ:HCM) Downgraded by Zacks Investment Research to Hold

Zacks Investment Research lowered shares of HUTCHMED (NASDAQ:HCM – Get Rating) from a buy rating to a hold rating in a research report released on Thursday, Zacks.com reports. According to Zacks, “Hutchison China MediTech Limited researches, develops, manufactures and sells pharmaceuticals and health-related consumer products. The Company offers drugs for oncology and autoimmune diseases treatment. […]

Related Keywords

China ,Hong Kong , ,Capital International Investors ,Schroder Investment Management Group ,Zacks Investment Research ,Deutsche Bank Aktiengesellschaft ,Blackrock Inc ,Hutchison China Meditech ,Nasdaq ,Get Rating ,China Meditech Limited ,Bank Aktiengesellschaft ,International Investors ,Investment Management Group ,State Street Corp ,Street Corp ,Hutchmed ,Nasdaq Hcm ,Phcm ,Medical ,Downgrade ,